Emerging nanotherapeutics for antithrombotic treatment

Area of Science:

• Biomedical nanotechnology
• Cardio-cerebrovascular diseases
• Thrombosis research

Background:

• Thrombus formation leads to insufficient blood flow and ischemia, causing severe cardio-cerebrovascular diseases.
• High morbidity and mortality rates underscore the need for effective antithrombotic strategies.
• Biomedical nanotechnology has significantly advanced the diagnosis and treatment of thrombotic disorders.

Purpose of the Study:

• To review recent advances in biomedical nanotechnology for thrombus theranostics.
• To overview emerging antithrombotic nanotherapeutics and diagnostic techniques.
• To discuss the clinical translation of nanotechnology-driven antithrombotic therapies.

Main Methods:

• Review of current literature on nanotechnology in thrombus diagnosis and treatment.
• Categorization of antithrombotic nanotherapeutics (targeting, stimuli-responsive, phase transition).
• Discussion of multifunctional nanosystems for combined theranostics.

Main Results:

• Nanotechnology enables advanced thrombus diagnosis.
• Emerging nanotherapeutics include targeted, stimuli-responsive, and phase transition systems.
• Multifunctional nanosystems offer combined diagnostic and therapeutic capabilities.

Conclusions:

• Biomedical nanotechnology shows great promise for developing novel antithrombotic strategies.
• Nanomedicines offer improved targeting, responsiveness, and multifunctionality for thrombotic disorders.
• Clinical translation requires careful consideration of design, advantages, and challenges.